A B STR A C T
The long-term impact of acromegaly on subjective w ell-being after treatment of G H excess is unclear. Therefore, w e evaluated quality of life by validated questionnaires in a cross-sectional study of 118 successfully treated acromegalic patients. The initial treatment w as transsphenoidal surgery in most patients (92% ), if necessary follow ed by radiotherapy or octreotide.
All patients w ere in remission at the time of assessment (G H, < 1.9 µg/liter; normal IG F-I for age). G eneral perceived w ell-being w as reduced compared w ith controls for all subscales (P < 0.001) as measured by the Nottingham Health Profi le and the Short Form-36. Acromegalic patients also had low er scores on fatigue (Multidimensional Fatigue Index) and anxiety and depression (Hospital Anxiety and D epression Scale). Radiotherapy w as associated w ith decreased quality of life in all subscales except for the Hospital Anxiety and D epression Scale, and w orsened quality of life signifi cantly, according to the fatigue scores. Somatostatin analog treatment w as not associated w ith improved quality of life. Independent predictors of quality of life w ere age (physical subscales and Nottingham Health Profi le), disease duration (social isolation and personal relations), and radiotherapy (physical and fatigue subscales).
In conclusion, patients cured after treatment for acromegaly have a persistently decreased quality of life despite long-term biochemical cure of G H excess. Radiotherapy especially is associated w ith a reduced quality of life.
IN ACRO MEGALY THE AIM of treatment is to decrease excessive serum GH and IGF-I concentrations to currently accepted concentrations, i.e. a serum GH less than 1.9 µg/liter ( 5 mU /liter) and a normal IGF-I for age. Medical or surgical treatment alone is able to reach these therapeutic targets in only 50-70% of the patients. However, combinations of diff erent treatment modalities are able to control GH/IGF-I concentrations in almost all patients (1, 2) .
GH concentrations less than 5 mU /liter (<1.9 µg/liter) and normal IGF-I concentrations are associated with normalization of the increased mortality risk (3, 4, 5) . Moreover, parameters related to (cardiovascular) morbidity are reduced when a GH less than 5 mU /liter (<1.9 µg/liter) is achieved. These observations indicate that we are able to improve the morbidity and mortality associated with acromegaly.
In acromegaly, excessive GH and IGF-I concentrations cause gradual changes in facial and acral appearances as well as in many internal tissues. After successful treatment of the GH excess, soft tissue swelling diminishes, and symptoms related to GH excess, such as perspiration and paresthesias, decrease. However, other acromegalic features persist due to irreversible changes, for instance in bone and cartilage, and acromegaly may cause arthropathy with invalidating complaints. These and other persisting eff ects of previous GH excess may affect the quality of life in patients despite long-term biochemical control. This topic receives increasing attention, and recently, Webb et al. (6) developed a disease-specifi c health-related quality of life questionnaire focusing on physical and psychological quality of life issues in patients with acromegaly. However, the long-term impact of acromegaly on subjective wellbeing after successful treatment of GH excess is unclear.
Therefore, in the present study we assessed quality of life in acromegalic patients cured after treatment for acromegaly. Most patients were initially treated by transsphenoidal surgery.
If necessary, other treatment modalities were additionally used, aiming at the above-mentioned biochemical criteria. We assessed quality of life by the disease-specifi c questionnaire, Acromegaly-Quality of Life (ACRO -QO L), and four other validated, health-related, quality of life questionnaires and compared the results to those of a control group with equal age and sex distributions. The purpose was to evaluate various physical and mental aspects of quality of life in cured patients with acromegaly.
SU BJECTS AN D M ETH O DS

Protocol
To assess quality of life in cured acromegaly, we identifi ed all patients who were considered cured based on recent biochemical evaluation and were currently being followed in our center. The selection consisted of 1) our cohort of patients treated primarily with transsphenoidal surgery aiming at establishing immediate cure and, if necessary, treated by adjuvant treatment in the form of radiotherapy and/or somatostatin analogs; and 2) all patients initially treated with somatostatin analogs or radiotherapy who were followed in our center. Cure (or control during somatostatin analogs) was defi ned by a normal serum IGF-I level for age and a serum GH level below 1.9 µg/liter for all patients, and also by a normal GH suppression during oral glucose loading only in the patients without somatostatin analog treatment.
A total of 131 patients were asked to participate, and questionnaires were sent to their homes in prepaid envelopes. After 6 wk, nonresponders received a reminder letter, and thereafter they were contacted by telephone to encourage completion and return of the questionnaires. Each patient was also asked to provide a control person of comparable age and sex (a relative, friend, or neighbor) to compose a control population with a comparable socioeconomic status derived from the same geographical area. In addition to the control group derived from the environment of the patients, we used literature reference data for healthy samples of the Dutch and west European population from studies reporting normal values. These normal data are based on larger study populations than our own controls and thus are not aff ected by a potentially positive selection of the patient.
Primary study parameters were the results of a disease-specifi c and four health-related quality of life questionnaires. The outcomes were related to patient characteristics (age and sex), treatment modalities (surgery, radiotherapy, somatostatin analogs), duration and severity of GH excess (remission or active disease during assessment, duration of disease before start of treatment, the duration of active disease, and serum GH and IGF-I concentrations at the time of the questionnaire), and presence of hypopituitarism, defi ned as the need for replacement therapy.
The study protocol was approved by the medical ethics committee of Leiden University Medical Center, and all subjects returning completed questionnaires gave written consent for participation in the study.
Patients and controls
One hundred and eighteen questionnaires completed by patients were received of 131 sent (90%). Seven patients preferred not to participate in the study. Thus, the response rate was 95%. The treated patient group consisted of 61 male and 57 female patients, with a mean age of 58.6 ± 12.9 yr (range, 29-89 yr). Patient characteristics are detailed in Table 1 .
Eighty-three controls returned the questionnaires (response rate of 53%). The mean age was 56.8 ± 13.5 yr, and there were 36 male and 47 female controls. Age and sex were not diff erent between patients and controls (P = 0.47 and P = 0.26, respectively).
Questionnaires
Short Form-36 (SF-36). The SF-36 questionnaire comprises 36 items and records general wellbeing during the previous 30 d (7, 8) Nottingham Health Profi le (NHP). The Nottingham Health Profi le is frequently used in patients with pituitary disease to assess general well-being and consists of 38 yes/no questions, which are subdivided into six scales assessing impairments, i.e. pain (eight items), energy level (three items), sleep (fi ve items), emotional reactions (nine items), social isolation (fi ve items), and disability/functioning, i.e. physical mobility (eight items) (11, 12) . Subscale scores are calculated as a weighted mean of the associated items and are expressed as a value between 0 and 100. The total score is the mean of the six subscales. A higher score is associated with a worse quality of life. Age-related west European reference values were derived from the study by Hinz et al. (13) .
MFI-20. MFI-20 comprises 20 statements to assess fatigue, which are measured on a fi ve-point scale (14) . Five diff erent dimensions of fatigue (four items each) are calculated from these statements: 1) general fatigue, 2) physical fatigue, 3) reduced activity, 4) reduced motivation, and 5) mental fatigue. Scores vary from 0-20; a high score indicates greater fatigue. Agerelated Dutch reference values were derived from the study by Smets et al. (15) .
HADS.
The hospital anxiety and depression scale consists of 14 items pertaining to anxiety and depression, which are measured on a four-point scale. Scores for the anxiety and depres- After surgery and radiotherapy, the combination of glucose-suppressed serum GH less than 0.38 µg/liter, serum GH less than 1.9 µg/liter, and normal IGF-I for age was used to defi ne cure, whereas during medical treatment a serum GH less than 1.9 µg/liter and normal IGF-I were used to indicate control of disease. To facilitate reading of the present manuscript, patients with controlled disease during somatostatin analog treatment were also designated cured.
Treatment characteristics
Transsphenoidal surgery was performed in a single surgeon setting and was the treatment of fi rst choice from 1977 onward in most patients.
Radiotherapy was used to treat postoperative persistent acromegaly or prophylactically in some patients with postoperative cure but suspected incomplete tumor removal. Two patients were primarily irradiated. Conventional radiotherapy was given using a linear ac-celerator (8 mEV; total dose, 40 Gy, divided in fractions of 2 Gy) by a rotational fi eld technique or by a two-fi eld technique in a minority of patients. None of the patients was treated by stereotactic radiotherapy.
Medical treatment was used as the preferred adjuvant secondary treatment option since the introduction of the somatostatin analog octreotide. From the availability of depot preparations of octreotide (Sandostatin LAR; Novartis Pharma AG, Basel, Switzerland) or lanreotide (Lanreotide Autogel; Ipsen Biotech, Paris, France), these formulations are used as primary or secondary treatment option.
Treatment for hypopituitarism was started as necessary, based on the postoperative or yearly follow-up evaluations. The thyroid and (male) gonadal axis were assessed by basal hormone measurements, whereas the adrenal axis was evaluated by CRH stimulation test.
In premenopausal women hypogonadism was diagnosed by oligomenorrhea or amenorrhea and low gonadotropin levels. In the present study hypopituitarism was defi ned as the need for replacement therapy for one or more axes. Patients in this study were not routinely screened for GH defi ciency.
Statistics SPSS for Windows version 11.0 (SPSS, Inc., Chicago, IL) and Systat version 10.2 (Systat, Inc., Richmond, CA) were used to perform data analysis. Data were expressed as the mean ± SD unless otherwise mentioned. We used two-tailed t tests for unpaired data and the χ 2 test
to compare means of the diff erent groups. Independent variables aff ecting quality of life were explored with stepwise linear regression analysis. Literature reference data used were weighted means according to the age distribution in our cohort.
RESULTS
Patient and treatment characteristics
Clinical characteristics of the patients are detailed in Table 1 . Primary transsphenoidal surgery was performed in 108 patients. The other patients were treated initially with octreotide (n = 7) or radiotherapy (n = 2), whereas one patient was in remission after pituitary apoplexy.
The treatment outcome and follow-up of the patients responding to the questionnaire are detailed in Fig. 1 .
At the present evaluation all 118 patients were considered cured (91 by surgery and/or radiotherapy or apoplexy and 27 during somatostatin analog treatment) according to glucose-suppressed serum GH, random GH, and IGF-I levels. These biochemical fi ndings were corroborated by the fi ndings at previous yearly assessments. The mean estimated duration of disease until cured (date of cure minus the estimate date of onset disease) was 9.9 ± 8.2 yr Two patients with clinically and biochemically suspected GH defi ciency after radiotherapy for acromegaly were treated by recombinant human GH (rhGH) replacement. Eleven patients had serum IGF-I concentrations below the normal range for age, but no symptoms of GH defi ciency, and these patients did not receive rhGH replacement.
General perceived health in patients treated for acromegaly and controls (Table 2) Compared with our own controls, patients cured after treatment for acromegaly had a reduced quality of life according to all questionnaires and for all assessed items. This fi nding was consistent between the comparable items of diff erent questionnaires, assessed by highly signifi cant correlations between those items (data not shown). According to the SF-36, we observed reduced physical and social functioning, limitations in role functioning due to both emotional and physical problems, increased pain, and decreased general well-being. The corresponding items of the NHP supported these fi ndings, and the sleep score was signifi cantly worse in treated acromegalic patients compared with controls. All subscales of fatigue as assessed by the MFI-20 were aff ected, especially general fatigue, physical fatigue, and activity level. According to the HADS, both anxiety and depression scores were signifi cantly higher compared with control values. Forty-three patients (36%) had elevated scores for anxiety and depression (total HADS score, 13 or more).
When data were compared with the Dutch or west European age-adjusted mean reference values available from the literature (Table 2 ), role limitations due to physical and emotional Data shown are mean ± SD. 1 Patients compared with own controls by the unpaired two-tailed Student' s t-test. 2 Patients compared with literature reference data by the unpaired two-tailed Student' s t-test.
problems (SF-36) and energy and physical ability (NHP) were especially reduced compared with the general population. Also, general health perception was signifi cantly reduced. For the other items, slightly reduced values were found in cured patients.
Disease-specifi c questionnaire (ACRO-QOL)
After long-term cure following treatment for acromegaly, items of the ACRO-QOL ranged from 63.1 ± 22.1 on the appearance scale, 64.0 ± 21.2 on the physical performance subscale, and 78.3 ± 14.9 on the personal relations subscale. The total score was 68.3 ± 16.9 (see Table 3) on a scale of 0-100.
Factors aff ecting quality of life in cured acromegalic patients
Gender. No signifi cant diff erences were observed between the cured male and female patients treated for acromegaly for any of the items assessed. Male patients had signifi cantly lower scores than male controls on all items (P < 0.001), except for depression (HADS) and pain (SF-36; P = NS). Female patients and controls had equal scores on emotional reaction (NHP), sleep (NHP), mental fatigue (MFI-20), anxiety (HADS), and depression (HADS; not signifi cant), but female patients performed worse than female controls on all other items (P < 0.001).
Age. In 118 cured acromegalic patients, we observed a weak relationship between age and motivation (MFI-20), and general health perception (SF-36).
GH excess-related parameters. No relationship was observed between current serum GH concentrations and IGF SD scores of patients and any of the quality of life parameters. In addition, the duration of active disease and the duration of remission did not correlate to any of the 
Linear regression analysis
Stepwise linear regression analysis was performed in a model including age, gender, duration of active acromegaly, duration of remission, actual serum GH and IGF-I, applied radiotherapy, and presence of depression/anxiety symptoms (total score, HADS) as independent variables and the questionnaire items as dependent variables to study factors determining quality of life in cured acromegaly. Actual serum IGF-I concentration and gender did not aff ect any of the scores in the regression model. As shown in Table 4 , age was a signifi cant independent predictor of physical function and role limitations due to a physical problem (SF-36), of re- GH excess aff ects health-related quality of life, for example, by interfering with body image, pain, energy, strength, and even mood and depression (19, 20, 21) . Structured quality of life research in patients with acromegaly has been subject to study in only few reports to date, although this important clinical topic now receives increasing attention (21) . No large studies are available on the eff ect of (surgical) treatment on quality of life scores in this rare disease.
The present study is the fi rst cross-sectional study to evaluate quality of life in patients after long-term successful treatment of acromegaly.
The response rate of this study was very high, because 90% of patients chose to participate, whereas only a minority did not want to participate due to perceived distress from the questionnaires. We believe that this would not have infl uenced the outcome of this study, because the characteristics of the patients not participating were not diff erent from the others in the study population. The use of controls from the same environment as the patient, but chosen by the patient, may have introduced a bias because controls with a good quality of life are more likely to be asked. Because of this potential bias and the lower response rate of controls, we also report age-adjusted literature data from studies specifi cally designed to explore quality of life in a healthy population. Our own controls indeed performed signifi cantly better interviews. To date, this questionnaire has been used in 22 Turkish patients with active (n = 10) and inactive (n = 12) acromegaly, and the total score was reported to be lower in active patients than in inactive patients (48.4 ± 13.1 vs. 70.8 ± 14.3). In addition, the total score correlated inversely with serum IGF-I concentrations and a validated depression questionnaire (Beck' s depression inventory). We found comparable scores for the ACRO-QOL total score in our treated patients as Deyneli et al. (22) found in their inactive patients. Interestingly, in our study lower scores on the personal relation subscale of the ACRO-QOL were also associated with a longer disease duration after adjustment for age. Further investigation is required to assess the value of the ACRO-QOL as a clinical follow-up parameter for evaluating the effi cacy of treatment.
The SF-36 was recently recommended for use in GH defi ciency and is now increasingly used in pituitary disease (23) . This questionnaire may be more sensitive to detect changes in quality of life in GH defi ciency and replacement studies than the most frequently used NHP questionnaire. In this study NHP scores were indeed infl uenced by the age of the patient, and we found some discrepancies between NHP and the other questionnaires; this may be a refl ection of the lower sensitivity due to the yes/no questions. Nondisease-specifi c quality of life surveys were conducted with 27 newly diagnosed acromegalic patients by Johnson et al. (25) . In these groups identical results were found even in those patients with suspected GH defi ciency. Interestingly, our patients scored worse than either group in the study by Page et al. (25) on the physical subscales, pain and health perception, but not on the emotional role and social functioning subscales ( Table 5 ).
The interpretation of the fi nding of signifi cant association between the anxiety and depression scores, as assessed with the HADS, and all other scores is not straightforward. It could be that the HADS is a very sensitive measure of quality of life. Alternatively, and perhaps more likely, increased feelings of anxiety and depression may modulate the experience of all other complaints (26) .
In this cross-sectional study we were not able to identify the treatment modality that resulted in the best quality of life. In this respect, only patients with long-term cure by a single surgical procedure without (partial) hypopituitarism were comparable to controls for some items. Irradiated subjects performed worse on general fatigue, reduced motivation, energy, physical mobility, and physical function. Others also have suggested a decreased quality of life in mental health (SF-36) and due to depression and decreased control of emotions (General Well-Being Schedule) in patients after pituitary irradiation (25) .
The somatotropic system interacts with cognition, mood, and well-being. However, the mechanism by which GH and IGF-I act is not well understood. In depressive states, reduced GH secretion or impaired GH release after stimuli is observed (27) . After institution of rhGH replacement in GH-defi cient patients, the decreased quality of life and mood scores improve in most reports. Therefore, a direct eff ect on the central nervous system, leading to mood disorders and decreased quality of life, may be present in GH disorders, although not assessed in GH excess states. Whether these eff ects are reversible has not been assessed in longitudinal studies. The decreased scores in the present cross-sectional study may be explained theoretically by irreversible GH/IGF-I induced changes in the central nervous system, may be caused by limitations due to persisting invalidating symptoms, or could be due to the psychological eff ects of living with a disease and its treatment. Also, long-term withdrawal eff ects may have led to irreversible alterations in perceived quality of life (28, 29) .
In summary, quality of life in long-term cured acromegalic patients is reduced compared with that in controls, as assessed by four health-related and one disease-specifi c question- 
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